Furthermore, SGLT2 inhibitors were significantly related to a reduced risk of AKI compared with GLP-1 receptor agonists (OR = 0.79) and DPP-4 inhibitors (OR = 0.68) [151]. The gene discussed is SLC5A2; the disease is acute kidney injury.